The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InGilead Sciences has announced a significant downward revision to its 2026 financial guidance, now projecting an adjusted loss between $0.65 and $1.05 per share. This revision comes despite the company beating Q1 estimates, a performance primarily driven by robust growth in HIV drug sales and the oncology treatment Trodelvy. The shift marks a dramatic reversal from previous earnings estimates of $8.45 to $8.85 per share, triggering an immediate negative reaction in the stock price. Gilead identified Ono Pharmaceutical as the key partner in the R&D collaboration responsible for the substantial charges. Analysts are now evaluating whether the long-term potential of the Ono partnership can offset these significant near-term costs. This update underscores the high capital intensity and financial risks inherent in developing innovative biotech pipelines.